Loading...
Loading...
IRON| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 30.9M |
| Operating I/L | -30.9M |
| Other Income/Expense | 4.6M |
| Interest Income | 4.6M |
| Pretax | -26.3M |
| Income Tax Expense | 0.1M |
| Net Income/Loss | -26.4M |
Disc Medicine, Inc. is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of novel treatments for serious hematologic diseases. The company's portfolio of therapeutic candidates targets fundamental biological pathways of red blood cell biology, focusing on heme biosynthesis and iron homeostasis. By addressing a spectrum of hematologic diseases, Disc Medicine aims to provide innovative treatments for patients in need. Its revenue model is based on the successful development and commercialization of these therapeutic candidates, which have the potential to generate revenue through sales and licensing agreements.
